Trichosporon pullulans infections are very rare and potentially fatal in patients with haematological malignancies and in bone marrow transplant recipients. Biochemical systems may present certain limitations for accurate identification of these new and uncommon yeast isolates. Our experience suggests that clinical features, radiological signs and proinflammatory markers including C-reactive protein, fibrinogen, and procalcitonin remain the mainstay for monitoring the efficacy of antifungal treatment in the presence of new and rare pathogen agents.
The Trichosporon species, emerging opportunistic agents, are well recognized as pathogens capable of causing systemic disease. Most of these infections, occurring in immunocompromised patients, are described in association with T. beigelii. T. pullulans is rarely reported as a fungal pathogen. Biochemical testing may prove difficult when used to identify these new and unusual organisms. We report a 67-year-old man who underwent a second autologous peripheral blood stem cell transplant (PBSCT) for light-chain multiple myeloma. He was conditioned with melphalan 140 mg/m 2 ; on day 0, he received cryopreserved PBSC (3.2 Â 10 6 CD34 þ cells/kg). Engraftment was prompt, neutrophil recovery 40.5 Â 10 9 /l and platelets 420 Â 10 9 /l occurring on days þ 11 and þ 12, respectively. Surveillance cultures were periodically performed from nasal, pharyngeal, rectal, urinary and skin swabs. He received antibacterial prophylaxis with ciprofloxacin (500 mg twice a day) and antifungal prophylaxis with fluconazole (100 mg orally once a day) starting from day À3. He became febrile from day þ 7. Chest X-ray was clear. Blood cultures, performed every 8 h and during each febrile episode, were negative. He was treated empirically with broad-spectrum antibiotics. Subsequent modifications to treatment were dictated by clinical and radiological signs and microbiological results. On day þ 9, a chest X-ray showed a single, faint, nonspecific nodular infiltrate in the left lower lobe, accompanied by persistent fever and modest dyspnoea. Cephalosporin was substituted for carbapenem, and intravenous voriconazole was commenced because of its tolerability and demonstrated superiority to conventional amphotericin against aspergillosis. 1 On day þ 12, a chest X-ray revealed multiple circumscribed nodular infiltrates; computed axial tomography showed mass-like infiltrates with no surrounding halo or ground-glass attenuation. Arterial blood gases showed marked hypoxia; the patient received 100% oxygen by mask at 6-12 l/min. Antifungal therapy was changed from voriconazole to intravenous caspofungin at a dose of 70 mg on day 1 and 50 mg subsequently; caspofungin was used because of its good tolerance and the fact that it has been shown to be effective as salvage treatment for invasive aspergillosis in patients refractory to other antifungal drugs, 2 and as primary treatment for invasive candidiasis. 3 It has also been used empirically in persistently febrile neutropenic patients. 4 Viral serology was negative, although it was not possible to perform specific virological studies or immunofluorescence for Pneumocystis carinii. Empirical treatment with trimethoprim-sulphamethoxazole and antiviral drugs was started. The patient's condition progressively deteriorated; the systolic blood pressure fell to 70 mmHg requiring inotropic support. On day þ 15, amphotericin B lipid complex (ABCL) 5 mg/kg was started, after stopping caspofungin. At 2 days after beginning ABCL, the patient became afebrile. Inotropic support was discontinued after 3 days, his respiratory function improved significantly, and the pulmonary infiltrates on chest X-ray resolved completely on day þ 37. The central venous catheter (CVC) was removed on day þ 13 and a new one inserted at the same site; cultures from the CVC tip were negative. At haematological recovery (day þ 17), a fibreoptic bronchoscopy was performed. Four 20 ml aliquots of sterile normal saline were instilled and retrieved by syringe. Bronchoalveolar lavage fluid (BAL) was sent for cytology and microbiological culture. Biopsies were not taken. The BAL culture was positive only for T. pullulans. A diagnosis of probable fungal pneumonia was made. Susceptibility tests of the isolate proved resistance to fluconazole and sensitivity to amphotericin. It was not possible to assess susceptibility to voriconazole or caspofungin; MICs were not performed. The patient is currently undergoing post-PBSCT follow-up with no signs of infection.
T. pullulans infections are very rare and potentially fatal in haematological malignancies and in bone marrow transplanted patients. 5, 6 In the last decade, infections with unusual and new fungal opportunists represent a significant problem in both treatment and identification. Histology remains the procedure of choice for certain diagnoses, but lung biopsies are not systematically performed because of concomitant thrombocytopenia. Thus, fibreoptic bronchoscopy is limited to BAL. Microbiological assessment is essential for aetiologic diagnosis. However, the identification systems available may have certain limitations for accurate and correct identification of uncommon yeasts.
This study reports the isolation of T. pullulans from BAL. The identification of T. pullulans relied only on the Vitek Yeast Biochemical Card (YBC) (bioMerieux Vitek Inc.), the isolate being identified at '97%' probability at 24 and 48 h. According to Holland et al, 7 biochemical tests of this system do not allow definitive differentiation of T. pullulans from certain species of the genus Cryptococcus. Fenn et al 8 experienced great difficulty with the YBC in identifying unusual yeasts such as Candida tropicalis, Candida krusei, Trichosporon species, and some Cryptococcus species. In this study, three Cryptococcus species were incorrectly identified as Trichosporon species. Dooley et al organisms. In a recent report 7, 10 of invasive pulmonary T. pullulans infections in two patients with chronic granulomatous disease, the results of molecular typing, performed from BAL to confirm the findings of the Vitek YBC, identified a variant of Cryptococcus albidus as the pathological agent, but missed T. pullulans.
In our patient, T. pullulans pneumonia occurred during prophylaxis with fluconazole. During treatment firstly with voriconazole and then caspofungin, pulmonary involvement worsened, but the pulmonary infiltrates resolved completely with ABCL. These observations are of particular clinical relevance. In vitro studies show the superiority of voriconazole over amphotericin for the treatment of trichosporonosis; 11, 12 in contrast, other studies support the efficacy of amphotericin as cryptococcosis treatment. 13 Thus, the pneumonia we describe may not have been due to T. pullulans but to Cryptococcus species for the following reasons: (1) the unexpected therapeutic failure of voriconazole, a drug undoubtedly effective against Trichosporon species in vitro; 14 and (2) the proven limited diagnostic value of YBC for correct differentiation of T. pullulans from certain species of the genus Cryptococcus. Unfortunately, it was not possible to perform direct microscopy or culture examination on special media or to send the BAL to a molecular biology laboratory.
In conclusion, our experience suggests that clinical features, radiological signs, and proinflammatory markers remain the major tools for monitoring the efficacy of antifungal treatment in the presence of new and rare pathogens. 
